Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 3/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675962 | 0.91 | GSK3B (0.40) | GSK3BCYP1A2GSK3AAAK1PIK3CD | |
| SCHEMBL18556896 | 0.88 | GSK3B (0.52) | GSK3BGSK3AAAK1HDAC6MAPK1 | |
| SCHEMBL16675934 | 0.81 | GSK3B (0.39) | GSK3BCYP1A2GSK3AAAK1HDAC6 | |
| SCHEMBL16682137 | 0.80 | GSK3B (0.50) | GSK3BGSK3AAAK1PIK3CDPIM1 | |
| SCHEMBL18556305 | 0.79 | AAK1 (0.43) | GSK3BGSK3AAAK1PIK3CDPIM1 | |
| SCHEMBL16675931 | 0.77 | CDK2 (0.37) | GSK3BCDK2MAPK1 | |
| SCHEMBL16675953 | 0.73 | GSK3B (0.39) | GSK3BCYP1A2GSK3AAAK1MAPK1 | |
| SCHEMBL16682115 | 0.73 | CRHR1 (0.36) | GSK3BCDK2 | |
| SCHEMBL16675965 | 0.72 | GSK3B (0.47) | GSK3BHDAC6MAPK1 | |
| SCHEMBL16682116 | 0.71 | GSK3B (0.44) | GSK3BCYP1A2GSK3AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | GSK3B 4407/4885CYP1A2 2648/4885GSK3A 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.